Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26041993 | 0.89 | PTPN11 (0.78) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL20399900 | 0.88 | PTPN11 (0.59) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL19785039 | 0.85 | PTPN11 (0.83) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL30296025 | 0.84 | PTPN11 (1.00) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL19785043 | 0.84 | PTPN11 (1.00) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL29167777 | 0.84 | PTPN11 (0.55) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL20399874 | 0.82 | PTPN11 (0.52) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL30561158 | 0.82 | PTPN11 (0.52) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL21154389 | 0.77 | PTPN11 (0.85) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL25514319 | 0.76 | PTPN11 (0.84) | PTPN11KCNH2EGFRMAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571199-B1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-06-20 | — | — | US | disclosed |
| CN-117327075-A | Bicyclic compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-110446709-B | Bicyclic compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2018136265-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018136265-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPN2 | PTPN11 12/4885KCNH2 4409/4885EGFR 381/4885 |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | PTPN11 13/4885KCNH2 3022/4885EGFR 727/4885 |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN6, PTPN1 | PTPN11 9/4885KCNH2 2888/4885EGFR 245/4885 |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN4 | PTPN11 9/4885KCNH2 2990/4885EGFR 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.